01681 CONSUN PHARMA
Closed Add to Porfolio| Key Financial Ratio (Fiscal Year: 12/2024) | |||
| Current | 3.32X | Oper Margin | 35.2% |
|---|---|---|---|
| LT Debt/Equity | 0.2% | Net Margin | 30.7% |
| Total Debt/Equity | 6.5% | Return on Equity | 22.2% |
| Price/Book | 2.43X | Return on Assets | 15.6% |
| (HKD 12.480) | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
| Net Profit (MHKD) | 968.27 | 864.71 | 765.68 | 721.84 | 591.96 |
|---|---|---|---|---|---|
| Net Profit Growth (%) | +12.0 | +12.9 | +6.1 | +21.9 | +563.4 |
| Earnings Per Share (HKD) | 1.179 | 1.093 | 0.968 | 0.901 | 0.724 |
| Earnings Per Share Growth (%) | +7.9 | +12.9 | +7.5 | +24.3 | +589.2 |
| Dividend Per Share (HKD) | 0.900 | 0.450 | 0.300 | 0.300 | 0.280 |
| P/E* (X) | 10.58 | 11.41 | 12.89 | 13.86 | 17.23 |
| Yield (%) | 7.21 | 3.61 | 2.40 | 2.40 | 2.24 |
| Dividend Share (%) | 76.32 | 41.16 | 30.98 | 33.31 | 38.66 |
| Book NAV (HKD) | 5.130 | 4.929 | 4.370 | 3.885 | 3.215 |
| Auditors' Opinion | Unqualified | Unqualified | Unqualified | Unqualified | Unqualified |
Remarks:
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
Last Update Time: 2025-07-22 21:40:20
Latest Result
| (RMBMn) | 2024-12 | 2023-12 | Chg* (%) | 2022-12 |
| Cover Period (mths) | 12 | 12 | NA | 12 |
|---|---|---|---|---|
| Turnover | 2,967 | 2,590 | +14.6 | 2,340 |
| Operating Result | 1,021 | 864.549 | +18.1 | 747.611 |
| Associates | -0.066 | 0 | N/A | 0 |
| Profit Before Taxation | 1,020 | 863.703 | +18.1 | 746.393 |
| Taxation | 102.732 | 77.149 | +33.2 | 62.696 |
| Profit /( Loss) After Taxation | 917.374 | 786.554 | +16.6 | 683.697 |
| Minority Interests | 6.916 | 2.02 | +242.4 | 0.79 |
| Net Profit | 910.458 | 784.534 | +16.1 | 682.907 |
| Earnings Per Share () | 1.1792 | 1.0933 | +7.9 | 0.9684 |
| Dividend Per Share () | 0.9000 | 0.4500 | +100.0 | 0.3000 |
| Announcement Date | 2025-03-26 | 2024-03-28 | NA | 2023-03-23 |
* Annualised
Last Update Time: 2025-07-22 21:40:25
